In continuation of my update on Archexin (Archexin(R) was fromerly named as RX-0201, is an oligonucleotide with 20 mers..c ompound that inhibits the expression of human Akt-1.)...
Rexahn submits Phase II protocol for Archexin clinical study for ovarian cancer: Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol for the clinical study of Archexin as a treatment of ovarian cancer to the U.S. Food and Drug Administration (FDA).
No comments:
Post a Comment